斯邁旭生物成立于2022年10月，創始人為清華大學饒燏教授，公司最早在全球開展了“單分子雙靶”靶向蛋白降解（PROTAC）藥物的開發，并率先在國內開展了抗體偶聯降解劑（DAC）平臺的建立和相關藥物的研發。公司管線主要聚焦于自免及腫瘤領域，定位于BIC及FIC，致力于解決難成藥靶點及目前未被滿足的迫切臨床需求的挑戰。斯邁旭于2024年12月獲頒《北京市專精特新中小企業》，并于2026年1月與清華大學聯合獲批蛋白降解與分子膠藥物北京重點實驗室。
SmashBio was founded in October 2022 by Professor Rao Yu from Tsinghua University. The company pioneered the development of "single-molecule dual-target" targeted protein degradation (PROTAC) drugs globally and was the first in China to establish an antibody-conjugated degrader (DAC) platform and conduct related drug R&D. Its pipeline primarily focuses on autoimmune diseases and oncology, aiming for Best-in-Class (BIC) and First-in-Class (FIC) status, dedicated to overcoming challenges associated with undruggable targets and addressing urgent unmet clinical needs.
In December 2024, SmashBio was recognized as a "Beijing Specialized, Refined, Unique, and Innovative Small and Medium Enterprise". Furthermore, in January 2026, it jointly established the "Beijing Key Laboratory for Protein Degradation and Molecular Glue Drugs" with Tsinghua University.